Phase 4 N=50 Improving Asthma Control in the Real World: A Systematic Approach to Improving Dulera Adherence
Asthma
Primary: Asthma Control — 1.857; 1.592; 1.792; 1.578 units on a scale — p=0.046
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=100 Intravenous Acetaminophen in Craniotomy
Postoperative Pain
Primary: Post-Operative Opioid Requirement — 11.0; 10.1 Morphine Equivalents
Phase 4 N=100 The Effect of Dexmedetomidine Infusion on Post-operative Cognitive Function and Oxidative Stress in Cardiac Surgery
Oxidative Stress · Cognition Disorders
Primary: Numbers of Participants With Postoperative Cognitive Dysfunction (POCD) — 12; 8 Participants — p=0.289
Phase 4 N=54 Telmisartan as an Adjunctive Treatment for Metabolic Problems in Patients With Schizophrenia
Schizophrenia · Schizoaffective Disorder
Primary: Insulin Resistance — 1.9997; 2.5824 HOMA-IR scores
Phase 4 N=23 Control of Cognition (Naltrexone, Methylphenidate, and ADHD Study (NMAS))
Healthy · Attention Deficit Hyperactivity Disorder
Primary: Reaction Time Variability on the Multi-Source Interference Task — .22; .23; .26; .20 seconds — p=.02
Phase 4 N=144 Metabolic Effects of Antipsychotics in Children
Aggression · Attention Deficit-Hyperactivity · Oppositional Defiant Disorder
Primary: Change in DEXA % Body Fat — 1.81; 4.12; 1.66 percent body fat — p=<0.0001
Phase 4 N=16 Development of a PET-MR Myocardial Perfusion Examination Using Regadenoson
Ischemic Heart Disease
Primary: Diagnostic Accuracy of Cardiac PET/MRI Examination — 50; 64; 61; 64 percentage — p=0.35
Phase 4 N=24 Evaluating Treatment Resistant Dermatitis TaroIIR
Atopic Dermatitis · Psoriasis
Primary: Investigator Global Assessment- Atopic Dermatitis — 1.7; 1.5 units on a scale
Phase 4 N=65 Liposomal Bupivacaine for Post Operative Pain After Knee Replacement Surgery
Post-operative Pain
Primary: Pain Intensity at Movement — 8.95; 7.91 VAS Scale
Phase 4 N=13 Effects of N-acetylcysteine on Cardiorespiratory Control in COPD Patients With Mild-to-moderate Airflow Obstruction
Pulmonary Disease, Chronic Obstructive
Primary: Plasma Redox Status - Circulating Glutathione — 8.97; 7.05 micromolar
Phase 4 N=89 Safety and Tolerability Study of Pirfenidone in Combination With Nintedanib in Participants With Idiopathic Pulmonary Fibrosis (IPF)
Idiopathic Pulmonary Fibrosis
Primary: Percentage of Participants Who Complete 24 Weeks of Combination Treatment on Pirfenidone at a Dose of 1602-2403 mg/Day and Nintedanib at a Dose of 200-300 mg/Day — 77.5…
Phase 4 N=8 A Study to Evaluate the Pharmacokinetics (PK) of Darunavir (DRV) and Cobicistat (COBI) After a Single Oral Administration of Darunavir/Cobicistat Fixed-Dose Combination in Healthy Japanese Adult Participants
Healthy
Primary: Maximum Observed Plasma Concentration (Cmax) — 5496; 832 nanogram per milliliter (ng/mL)
Phase 4 N=62 MI Varnish for the Prevention of White Spot Lesions
White Spot Lesion · Orthodontic Treatment
Primary: Enamel Decalcification Index (EDI) Scores — 1.038; 1; 1.308; 2.724 scores on a scale
Phase 4 N=34 Guanfacine in Children With Tic Disorders
Tourette Disorder · Tourette Syndrome
Primary: Yale Global Tic Severity Scale (YGTSS) — 24.72; 23.56; 15.00; 12.94 units on a scale
Phase 4 N=140 Tailored Use of Tirofiban for Non-ST-elevation Acute Coronary Syndrome Patients
Non-ST Elevation Myocardial Infarction
Primary: Area Under Curve of Serial Cardiac Biomarkers — 197.2; 38.0; 121.4; 252.5 Hours*ng/ml